AGENDA
07:00 A.M. – 08:00 A.M.
Registration and Breakfast
08:00 A.M. – 08:05 A.M.
Welcome
Joaquina Baranda, MD, George and Floriene Lieberman Professor, Medical Director
Early Phase Program, The University of Kansas Cancer Center
ACCREDITED CONTINUING EDUCATION SESSIONS
08:05 A.M. – 08:25 A.M
The University of Kansas Cancer Center
Scott Weir, PharmD, PhD, Associate Director for Translational Research; Director, Institute for Advancing Medical Innovation; Professor, Pharmacalogy, Toxicology, and Therapeutics, The University of Kansas Cancer Center; University of Kansas Medical Center
08:25 A.M. – 09:05 A.M.
Keynote Presentation: Evolution and Transformation of Cancer Clinical Trials—from Personal Experience and Perspective
Weijing Sun, MD, FACP, Sprint Professor of Medical Oncology, Professor of Medical Oncology and Cancer Biology, Director of Medical Oncology Division
University of Kansas Medical Center
Associate Director for Clinical Research
The University of Kansas Cancer Center
09:05 A.M. – 09:25 A.M.
CAR-T: Continuation in a Revolution of Cancer Therapeutics
Joseph McGuirk, DO, Schutte-Speas Professor of Hematology-Oncology, Division Director, Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplant
University of Kansas Medical Center, The University of Kansas Cancer Center
09:25 A.M. – 09:45 A.M.
Addressing Tobacco-Related Health Disparities in the African American Community
Nikki L. Nollen, PhD, Professor, Department of Population Health
University of Kansas Medical Center
Co-Leader, Cancer Prevention and Control Program
The University of Kansas Cancer Center
09:45 A.M. – 10:05 A.M.
Illuminating the Dark Genome
Jennifer Gerton, PhD, Investigator and Dean
The Graduate School of the Stowers Institute for Medical Research
Professor, Department of Biochemistry and Molecular Biology
University of Kansas School of Medicine
10:05 A.M. – 10:35 A.M.
BREAK
NON-ACCREDITED SESSIONS
10:35 A.M. – 10:55 A.M.
Breaking Barriers: Targeted Therapy Development in Rare and Hard-to-Treat Cancers
Islam Hassan, MD, Senior Medical Director, Vorasidenib Clinical Lead
Servier Pharmaceuticals
10:55 A.M. – 11:15 A.M
Regeneron from Science to Pipeline
Teresa Ramirez Montagut, MD, PhD, Global Head GI, GU, Women’s Cancers, and Early Pipeline, Oncology Medical Affairs
Regeneron Pharmaceuticals
11:15 A.M. – 11:35 A.M.
Isatuximab in Multiple Myeloma: Scientific Updates
Lucia Casadei, PhD, Medical Science Liaison in Hematology-Oncology
Sanofi Pharmaceuticals
11:35 A.M. – 12:05 P.M.
PIVOT Panel Discussion
12:05 P.M. – 12:45 P.M.
LUNCH BREAK
ACCREDITED CONTINUING EDUCATION SESSIONS
12:45 P.M. – 01:05 P.M.
Triumphs and Setbacks of ADC Developments in Non-Small Cell Lung Cancer
Chao Hui Huang, MD, FACP, Clinical Professor, Division of Medical Oncology, Director of Thoracic Oncology, University of Kansas Medical Center, The University of Kansas Cancer Center
01:05 P.M. – 01:25 P.M.
The Roller Coaster of MRD Testing in Multiple Myeloma
Al-Ola Abdallah, MD, Associate Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center, The University of Kansas Cancer Center
01:25 P.M. – 01:45 P.M.
Looking Down the Pipeline at Breast Cancer Chemoprevention
Lauren Nye, MD, Associate Professor
University of Kansas Medical Center
Director of Breast Cancer Prevention Clinical Services
The University of Kansas Cancer Center
01:45 P.M. – 02:05 P.M.
Translation of Cancer Biology Discoveries into Novel Cancer Therapeutic Agents - An Overview of Drug Discovery and Development Process
Scott Weir, PharmD, PhD, Associate Director for Translational Research; Director, Institute for Advancing Medical Innovation; Professor, Pharmacalogy, Toxicology, and Therapeutics, The University of Kansas Cancer Center; University of Kansas Medical Center
02:05 P.M. – 02:25 P.M.
Financial Toxicity in Early Phase Clinical Trials for the Underrepresented
Kamiyah Hicks, BA, Post-Baccalaureate Research Intern, Early Phase Program
The University of Kansas Cancer Center
02:25 P.M. – 02:30 P.M.
Closing Remarks
Saqib Abbasi, MD, Assistant Professor, Early Phase Program, University of Kansas Medical Center
The University of Kansas Cancer Center
